SCHEDULE AT A GLANCE

<table>
<thead>
<tr>
<th>Day</th>
<th>Program Slots</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday 12/8/10</td>
<td>7:00-7:30</td>
</tr>
<tr>
<td>Thursday 12/9/10</td>
<td>8:00-8:15</td>
</tr>
<tr>
<td>Friday 12/10/10</td>
<td>9:00-9:30</td>
</tr>
<tr>
<td>Saturday 12/11/10</td>
<td>11:00-11:45</td>
</tr>
<tr>
<td>Sunday 12/12/10</td>
<td>12:00-12:45</td>
</tr>
</tbody>
</table>

For Exhibit Hours See Page ??
**Program Schedule**

**Wednesday, December 8, 2010**

12:00-7:00 **Registration – Bridge Hall**
Pre-registered attendees can obtain materials. Those who have not yet registered may do so.

2:00-7:30 **Educational Sessions – Ballroom Level – Ballroom C**
An update on advances in the technologies available for translational research. Sessions are to provide people with a better understanding of the talks they hear using the techniques described. They also provide researchers with a guide to the techniques they should be considering for their studies.

2:00-3:30 **Educational Session**
**CNS Metastases in Breast Cancer: Current Challenges and Future Directions – Ballroom C-1**
Moderator: Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

- Advances in neurosurgery in the management of CNS metastases
  Elizabeth B. Claus, MD, PhD
  Yale University
  New Haven, CT
- Radiation therapy for CNS metastases: What should the standard approach be?
  Minesh P. Mehta, MD
  University of Wisconsin School of Medicine and Public Health
  Madison, WI
- Systemic therapy for CNS metastases
  Nancy U. Lin, MD
  Dana-Farber Cancer Institute
  Boston, MA

2:00-3:30 **Educational Session**
**DNA Repair – Ballroom C-3**
Moderator: Daniel P. Silver, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

- DNA repair pathways and tumorigenesis
  James M. Ford, MD
  Stanford University Medical Center
  Stanford, CA
- DNA repair and breast cancer: Therapeutic opportunities and challenges
  Daniel P. Silver, MD, PhD
  Dana-Farber Cancer Institute
  Boston, MA

4:00-5:30 **Educational Session**
**Design & Interpretation of Biomarker Studies – Ballroom C-1**
Moderator: Mitchell Dowsett, MD, PhD
Royal Marsden Hospital NHS Trust
London, UNITED KINGDOM

- Statistical challenges in predictive and prognostic biomarker studies: How to avoid wasting your time and specimens
  Lisa M. McShane, PhD
  National Cancer Institute
  Bethesda, MD
- The importance of technical validation
  Jorge Reis-Filho, MD, PhD, MRCPath
  Breakthrough Breast Cancer Research Center
  The Institute of Cancer Research
  London, UNITED KINGDOM
- Interpretation of biomarker studies
  Lajos Pusztai, MD, DPhil
  Breakthrough Breast Cancer Research Center
  The Institute of Cancer Research
  London, UNITED KINGDOM

4:00-5:30 **Educational Session**
**Emerging Radiation Techniques – The Fast and the Furious – Ballroom C-2**
Moderator: Richard Crowrowver, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

- Rationale and results of accelerated partial breast irradiation
  Frank A. Vicini, MD, FACR
  William Beaumont Hospital
  Royal Oak, MI
- Radiosurgery and stereotactic body radiotherapy
  Richard Crowrowver, MD, PhD
  UT Health Science Center San Antonio
  San Antonio, TX

4:00-5:30 **Educational Session**
**Automated, Quantitative Cell and Tissue Imaging Technologies – Ballroom C-3**
Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX
Measuring and modeling cell death pathways in tumor cells
Peter K. Sorger, PhD
Harvard Medical School
Boston, MA

Quantitative methods to assess eligibility for breast cancer therapy
David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, CT

Educational Session
Next Generation Sequencing for the Clinician – Ballroom C-1
Moderator: Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

Next-generation sequencing and analysis of tumor/normal pairs
Elaine R. Mardis, PhD
Washington University
St. Louis, MO

Leveraging next generation sequencing in the study of breast cancer somatic genetics
Andrew Futreal, PhD
Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM

Educational Session
Next Generation Sequencing for the Clinician – Ballroom C-1
Moderator: Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

Next-generation sequencing and analysis of tumor/normal pairs
Elaine R. Mardis, PhD
Washington University
St. Louis, MO

Leveraging next generation sequencing in the study of breast cancer somatic genetics
Andrew Futreal, PhD
Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM

THURSDAY, DECEMBER 9, 2010
7:00-8:30 Career Development Forum: A Networking Session for Young Investigators – Ballroom B
Networking and career development opportunities for early-career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the SABCS. Space in the workshop is limited to 135 participants; registrations will be accepted on a first-come, first-served basis and is free of charge. Please complete the registration form on page ??, Discussion topics include Careers in Government; Careers in Industry, Careers in Translational Research, Grant Writing – Basic/Translational, Grant Writing – Clinical, How to Get the Most Out of Your Fellowship Years, How to Make the Most Out of Being A Cooperative Group Member, Making the Transition to Independence, Mentoring and Supervising, Negotiating a Job Offer or Promotion, Oral Presentation Skills, Publication Strategies, Searching for a Job and interviewing, Setting Up and Managing a Laboratory, The Path Leading to Clinical Trials

8:30-8:45 WELCOME – Exhibit Hall D
Opening Remarks
C. Kent Osborne, MD
Peter M. Ravdin, MD, PhD

8:45-9:15 PLENARY LECTURE 1 – Exhibit Hall D
Metabolic Reprogramming of Cancer Cells and Therapeutic Opportunities
Chi Van Dang, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, MD
1. Final analysis of NCIC CTG MA.27: A randomized phase III trial of Exemestane versus Anastrozole in postmenopausal women with hormone receptor positive primary breast cancer
Goss PE, Ingle JN, Chapman J-AW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L, Pritchard KI. Massachusetts General Hospital, Boston, MA, Mayo Clinic, Rochester, MN, Queen’s University, Kingston, ON, Canada, Washington University, St Louis, MO, Indiana University Simon Cancer Center, Indianapolis, Cleveland Clinic, OH, University Institute of Medical Oncology INsepsital, Beme, Switzerland, British Columbia Cancer Agency, Vancouver, BC, Canada, Sunnybrook Health Sciences Centre, Toronto, ON.

12. ACOSOG Z1031: A randomized neoadjuvant comparison between Letrozole (LET), Anastrozole (ANA) and Exemestane (EXE) for postmenopausal women with ER Rich stage 2/3 breast cancer: Biomarker outcomes and the predictive value of the baseline PAM50 based intrinsic subtype

13. A comparison of Fulvestrant 500 mg with Anastrozole as first-line treatment for advanced breast cancer: Follow-up analysis from the ‘FIRST’ study
Robertson JFR, Lindemann JP, Llombart-Cussac A, Rolski J, Felt D, Dewar J, Emerson L, Dean A, Ellis MJ. University of Nottingham, United Kingdom, AstraZeneca, United Kingdom, Hospital Arnau de Vilanova Lleida, Spain, Centrum Instytut im M, Sklodowskiej-Curie, Krakow, Poland, FN Ostrava, Ostrava, Czech Republic, Ninewells Hospital and Medical School, Dundee, United Kingdom, Washington University School of Medicine, St Louis.

14. A randomized, placebo-controlled, phase 2 study of AMG 479 with Exemestane (E) or Fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) locally advanced (LA) or metastatic (M) breast cancer (BC)

15. Interaction between Goserelin and Tamoxifen in a controlled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer
Sverrisdottir A, Johannson H, Johannson U, Bergh J, Rotstein S, Rutquist LE, Fornander T. Karolinska Institutet and University Hospital, Stockholm, Sweden, Landspitali University Hospital, Reykjavik, Iceland, School of Cancer & Enabling Sciences, University of Manchester & Paterson Institute, Medical Oncology Breast Unit, Christie Hospital, Manchester, United Kingdom.

16. TAMRAD: A GINECO randomized phase II trial of Everolimus in combination with Tamoxifen versus Tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to Aromatase inhibitors (AI)
2010 PROGRAM

1:45-2:45 MINI-SYMPOSIUM 1 – Exhibit Hall D

noncodingRNA - The New Frontier
Moderator: Saraswati Sukumar, PhD
Johns Hopkins University School of Medicine
Baltimore, MD

Long noncoding RNAs in breast cancer progression
Howard Y. Chang, MD, PhD
Stanford University School of Medicine
Stanford, CA

MicroRNA in medical practice
George A. Calin, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

2:45-3:00 GENERAL SESSION 2 – Exhibit Hall D

21. Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer

22. Multivariate analysis of obesity and disease free survival in patients with nodal positive primary breast cancer - The ADEBAR trial

23. The impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; exploratory analysis from the TEAM study
Sevastyanova C, Hille E, Hasenburg A, Rea D, Markopoulos C, Hozumi Y, Putter H, Nortier JH, van der Velde C. Erasmus MC. Daniel den Hoed Cancer Center, Rotterdam, Netherlands, Leiden University Medical Center, Netherlands, University Hospital Freiburg, Germany, The University of Birmingham, United Kingdom, Athens University Medical School, Athens, Greece, Ichi Medical University, Shimotsuke, Japan, Sint Augustinus, Wilrijk, Belgium.

24. Final results of a prospectively planned biomarker analysis: HER1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus Tamoxifen in the TEAM pathology sub-study
Bartlett JMS, Brookes CL, van der Velde CHJ, Stocken D, Campbell FM, Hasenburg A, Kay C, Kiebeck D, Markopoulos C, Meershoek-Klein Kranenburg E, Mallon EA, Dirix L, Robson T, Sevastyanova C, Rea DW. University of Edinburgh, United Kingdom, University of Birmingham, United Kingdom, Leiden University Medical Centre, Netherlands, University Hospital Freiburg, Germany, Helios Medical Centre, Aue, Germany, Athens University Medical School, Athens, Greece, Western Infirmary, Glasgow, United Kingdom, AZ Augustinus, Antwerp, Belgium, Erasmus MC, Rotterdam, Netherlands.

25. Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumours identifies determinants of response
Dunbier AK, Ghazouzi Z, Anderson H, Smith IE, Dowsett M. Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, London, United Kingdom.

4:00 26. Aromatase inhibitors and risk of myocardial infarction, stroke and fracture

4:15 27. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients
Amir E, Ocana A, Niraula S, Carlsson L, Seruga B. Princess Margaret Hospital, Toronto, ON, Canada, Princess Margaret Hospital, Toronto, ON, Canada, Institute of Oncology, Ljubljana, Slovenia.

4:30-5:30 SUSAN G. KOMEN FOR THE CURE BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Exhibit Hall D

The Basic Science award is presented to a researcher who has added substantively to our understanding of the basic biology of, or development of, methodologies that further our ability to unravel the genetic and molecular basis of breast cancer. This year the award is being presented to:

Jeffrey M. Rosen, Ph.D.
Baylor College of Medicine
Houston, TX

Lecture Topic: Targeting of Breast Cancer Tumor Initiating Cells
The Clinical Research award is presented to a clinician who has significantly furthered the identification of new prevention, detection or treatment approaches for breast cancer and its translation into clinical care. This year the award is being presented to an outstanding team:

Sooomyung “Soon” Paik, MD
NSABP Foundation Inc.
Pittsburgh, PA

Lecture Topic: “Prediction of benefit from systemic adjuvant therapies for breast cancer”
33. First results of the NeoALTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of Lapatinib, Trastuzumab, and their combination plus Paclitaxel in women with HER2-positive primary breast cancer
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H, Dinif P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M. On behalf of the NeoALTO Study Team. Vall d’Hebron University Hospital, Barcelona, Spain, FSS Ltd, Kincraig, United Kingdom, University Hospital Kiel, Germany, Breast Cancer Center Vall d’Hebron University Hospital and SOLTi (Spanish Breast Cancer Research Group), Barcelona, Spain, Institut Jules Bordet and Breast European Adjuvant Study Team, Brussels, Belgium, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru, Breast International Group, Brussels, Belgium, SOLTi (Spanish Breast Cancer Research Group), Barcelona, Spain, Breast European Adjuvant Study Team, Brussels, Belgium, GlaxoSmithKline, Collegeville, PA, European Institute of Oncology, Milan, Italy, National Cheng Kung University Hospital, Tainan, Taiwan, National Institute of Oncology, Budapest, Hungary, Academic Hospital of the University Charite, Berlin, Germany, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Institut Jules Bordet, Brussels, Belgium.

34. Discussion
Eric P. Winer, MD, Dana-Farber Cancer Institute, Boston, MA

35. Discordance in hormone receptor and HER2 status in breast cancer during tumor progression
Lindstrom LS, Karlsson E, Wilking U, Bergh J. Karolinska Institute, Stockholm, Sweden; Karlstad Hospital, Karlstad, Sweden.

36. Combination therapy of the novel PI3K inhibitor GDC-0941 and dual PI3K/mTOR inhibitor GDC-0980 with Trastuzumab-DM1 antibody drug conjugate enhances anti-tumor activity in preclinical breast cancer models in vitro and in vivo

37. Kinome screening for regulators of estrogen receptor identifies a novel kinase as a new therapeutic target in breast cancer
Giamas G, Filipovic A, Jacob J, Shifa BA, Green AR, Ellis IO, Lenz H-J, Stebbing J. Imperial College, London, United Kingdom, Queen’s Medical Centre, Nottingham University Hospital, Nottingham, United Kingdom, University of Southern California, Norris Comprehensive Cancer Centre, Keck School of Medicine, Los Angeles, CA.

38. RNAi screening identifies the insulin/insulin-like growth factor-I receptor pathway as a mechanism of escape from hormone dependence in estrogen receptor-positive breast cancer
Fox EM, Miller TW, Ye F, Shyr Y, Arteaga CL. Vanderbilt- Ingram Comprehensive Cancer Center, Vanderbilt University, Nashville, TN.

11:30-12:00 AACR Distinguished Lectureship in Breast Cancer Research – Exhibit Hall D

Synthetic Lethal Approaches to Cancer Therapy
Alan Ashworth, PhD, FMedSci, FRS
Breakthrough Research Centre at The Institute of Cancer Research
London, UNITED KINGDOM

12:00-1:35 LUNCH BREAK

12:30-1:35 CASE DISCUSSION 1 – Ballroom A

12:30-1:35 BASIC SCIENCE FORUM – BALLROOM B

Managing Stress in Cancer Cells: New Druggable Pathways and Targets
Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
1:45-2:45 MINI-SYMPOSIUM 2 – Exhibit Hall D

Molecular chaperones: Cancer dependence and druggability
Paul Workman, PhD, DSc (Hon), FMedSci FSB
Cancer Research UK Centre of Cancer Therapeutics
The Institute Of Cancer Research
Sutton, UNITED KINGDOM

1. Recent U.S. trends in the local treatment of primary breast cancer
Todd M. Tuttle, MD, MPH
University of Minnesota
Minneapolis, MN

3:15-5:30 GENERAL SESSION 4 – Exhibit Hall D

41. FinXX final 5-year analysis: Results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer
Joensuu H, Kellokkumpu-Lehtinen P-I, Huovinen R, Jukkila-Vuotinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Bono P, Lindman H, On behalf of the FinXX Study Investigators. Helsinki University Central Hospital, Finland, Tampere University Hospital, Finland, Turku University Central Hospital, Finland, Oulu University Hospital, Oulu, Finland, Kanta-Hame Central Hospital, Hamenlinna, Finland, Gavle Hospital, Gavle, Sweden, Kuopio University Hospital, Kuopio, Finland, Uppsala University Hospital, Sweden.

42. First efficacy results of a randomized, open-label, phase III study of adjuvant Doxorubicin plus Cyclophosphamide followed by Docetaxel with or without Catecibamine in high-risk early breast cancer
9:00-9:30 \textbf{PLENARY LECTURE 3 – Exhibit Hall D}

\textbf{The Upside of Irrationality}

Dan Ariely, PhD
Duke University
Durham, NC

9:30-11:15 \textbf{GENERAL SESSION 5 – Exhibit Hall D}

51. Prospective long term outcomes for patients with micro- and macro-positive sentinel nodes: NSABP B-32 sentinel node trial

Julian TB, Anderson SJ, Golevskih N, Fourchotte Y, Mamosian ES, Wolmark N. NSABP Operations and Biostatistical Centers, Pittsburgh, PA, Allegheny General Hospital, Pittsburgh, PA, Virginia Hospital Center, Virginia Hospital, Arlington, VA, Institute Curie, Paris, France, Aultman Health Foundation, Canton, OH.

52. Latrogenic displacement of tumor cells to the sentinel node after surgical excision biopsy in primary breast cancer

Tvedskov TF, Jensen MB, Kromann N, Ballev E. Copenhagen University Hospital, Copenhagen, Denmark, Danish Breast Cancer Cooperative Group, Copenhagen, Denmark, Herlev Hospital, Herlev, Denmark.

10:00-11:15 \textbf{GENERAL SESSION 6 – Exhibit Hall D}

53. Is manual lymph drainage applied after axillary lymph node dissection for breast cancer effective to prevent arm lymphoedema? A randomised controlled trial


54. Synthetic lethality of triple-negative breast cancers via the MYC oncogene pathway

Goga A, Horie D, Kusid L, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Huskey NE, Creasman KW, Davis SE, Mills GB, Esserman LJ. University of California, San Francisco, Boston University School of Medicine, M.D. Anderson Cancer Center.

55. Identification of a clinically relevant gene signature in triple negative and basal like breast cancer

Rody A, Karm T, Liedtke C, Puszta L, Ruckhaberle E, Harker L, Gaetje R, Sollbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtich U, Kaufmann M. Goethe-University, Frankfurt, Germany, University of Muenster, Germany, University of Texas M.D. Anderson Cancer Center, Houston, Ludwig-Maximilians University, Munich, Germany, University of Hamburg, Germany.

56. Steroid hormone regulation of mammary stem cell function

Linderman GJ, Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin JT, Visvader JE. The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia, The Royal Melbourne Hospital, Melbourne, VIC, Australia, Prince Henry’s Institute of Medical Research, Clayton, VIC, Australia, Nagahama Institute for Biochemical Science, Nagahama, Shiga, Japan, St Vincent’s Institute, Fitzroy, VIC, Australia.
11:00  57. Estrogen receptor alpha negative (ER-) breast cancer stem cells in ER+ cell lines and primary cancers are enriched by Tamoxifen therapy
O'Brien CS, Howell SJ, Gandhi A, Gee J, Lykkesfeldt A, Nicholson RI, Clarke RB. University of Manchester, United Kingdom, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom, University Hospital of South Manchester, Manchester, United Kingdom, University of Cardiff, Wales, United Kingdom, Danish Cancer Society, Copenhagen, Denmark.

3:15  62. 313 patients with breast cancer during pregnancy - results from a prospective and retrospective registry (GBG-20/BIG02-03)
Loibl S, Amant F, Kaufmann M, Ring A, Sikelnik H, Gierzek J, Fehm T, Bontenbal M, Heinrigs M, Lenhard M, Scherr I, Mehta K, von Minckwitz G. German Breast Group, Neu-Ilsenburg, Germany, UZ Leuven Campus Gasthuisberg, Belgium, Universitäts-Frauenklinik Fankfurt a.M., Germany, Royal Sussex County Hospital, Brighton, United Kingdom, Cancer Center and Institute of Oncology, WARSAW, Poland, Universitäts-Frauenklinik Tubingen, Germany, Enasmus Medical Center, Rotterdam, Netherlands, Klinikum der Universität München, Germany, Klinikum der Universität München, Germany, Elisabeth Krankenhaus Kassel, Kassel, Germany.

11:15-12:00  William L. McGuire Memorial Lecture – Exhibit Hall D
Supported by GlaxoSmithKline
What Would Bill Do? Channeling Your Inner McGuire
George W. Sledge, Jr., MD
Indiana University Simon Cancer Center
Indianapolis, IN

3:30  63. Compliance with Mammographic Screening Guidelines from an Administrative Claims Database
Subar M, Lust SA, Lin W. Medco Research Institute, Franklin Lakes, NJ.

12:00-1:35  LUNCH

12:30-1:35  CASE DISCUSSION 2 – Ballroom A

12:30-1:35  BASIC SCIENCE FORUM – Ballroom B
Stem Cells - Defying Definition?
Moderator: Jorge Reis-Filho, MD, PhD, MRCPPath
Breakthrough Breast Cancer Research Center
The Institute of Cancer Research
London, UNITED KINGDOM

3:00-5:30  GENERAL SESSION 6 – Exhibit Hall D
3:00  61. Menopausal hormone therapy influence on cancer incidence and related cancer mortality in the Women’s Health Initiative Randomized Trials
Chlebowski RT. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.

5:00  65. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients

4:15  66. High independent prognostic and predictive value of circulating tumor cells in a large prospective multicenter trial including serum tumor markers in first line chemotherapy metastatic breast patients

4:45  67. Establishment and Characterization of Human Luminal Breast Cancer Xenografts

4:30  68. Hedgehog ligand overexpression predicts poor outcome in breast cancer and is a potential therapeutic target for metastatic disease
O‘Toole SA, Machalek D, Shearer R, Millar EKA, Nair R, Martelotto L, McLeod D, Cooper C, Ru Qi M, Sutherland RL, Watkins DN, Swarbrick A. Garvan Institute of Medical Research, Darlinghurst, NSW, Australia, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, University of NSW, Randwick, Australia, Sydney Medical School, Camperdown, NSW, Australia, St George Hospital, Kogarah, NSW, Australia, Monash Institute of Medical Research, Clayton, VIC, Australia, ICPMR Westmead Hospital, Westmead, NSW, Australia.

5:00  69. Expression of hedgehog proteins in the epithelial and stromal compartments of primary breast tumors and its prognostic significance
Ramaswamy B, Li X, Nuovo G, Lu Y, Shapiro CL, Majumder S. The Ohio State University, Columbus, OH.

TBA
5:30-7:30  POSTER DISCUSSION 9 & RECEPTION – Ballroom A
Obesity and Breast Cancer  901-908

5:30-7:30  POSTER DISCUSSION 10 & RECEPTION – Ballroom B
HER-2 and ER Testing  951-960

5:30-7:30  POSTER SESSION 5 & RECEPTION - Exhibit Halls A-B
(#5001-5169)
Detection/Diagnosis
Molecular, Functional, and Novel Imaging  5001-5016
Breast Imaging - Other Methods  5017-5030
Detection / Diagnosis – Other  5031-5034
Social, Behavioral, Economic and Outreach Studies
Quality of Life - Supportive Care  5035-5051
Palliation and Support (Pain Management)  5052
Treatment
Novel Targets and Targeted Agents  5053-5076
Signal Transduction Inhibitors  5077-5080
Her2-Targeted Therapy  5081-5114
Treatment – Other  5115-5123
Tumor Biology
Endocrine Therapy and Resistance  5124-5149
Metabolism and Breast Cancer  5150-5155
Etiology / Carcinogenesis  5156-5158
Gene Therapy  5159
Genetics - Germline Changes  5160-5163
Genetics - Somatic Changes  5164-5169

8:30-10:30  YEAR IN REVIEW
Moderator: C. Kent Osborne, MD, Baylor College of Medicine, Houston, TX
Advances in basic breast cancer research
Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX
Translational breast cancer research
Mitchell Dowsett, MD, PhD
Royal Marsden Hospital NHS Trust
London, UNITED KINGDOM
Early breast cancer
Aron Goldhirsch, MD
European Institute of Oncology
Milan, ITALY
Progress in advanced breast cancer
Lisa A. Carey, MD
University of North Carolina
Chapel Hill, NC
10:30  ADJOURNMENT

SUNDAY, DECEMBER 12, 2010
7:00-8:30  POSTER SESSION 6 & CONTINENTAL BREAKFAST – Exhibit Hall C
(#6001-6174)
Detection/Diagnosis
Diagnostic Pathology  6001-6020
Biopsy Techniques  6021-6022
Prognosis and Response Predictions
Prognostic Factors and Biomarkers - Clinical Testing and Validation II  6023-6061
Risk Factors, Epidemiology, and Prevention
Risk Factors and Modeling  6062-6073
Social, Behavioral, Education, and Outreach Studies
Education  6074-6078
Doctor-Patient Communication  6079-6082
Treatment
Anti-angiogenic Therapy  6083-6093
Antibody-Based Regimens  6094-6096
New Drugs and Treatment Strategies  6097-6117
Tumor Biology
Molecular Profiles  6118-6133
Genomics  6134-6139
Tumor Progression, Invasion, and Metastasis  6140-6174